glp-1 receptor agonists and cardiovascular outcome trials an update mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Table 1 from Cardiovascular Effects
Description
For tech transfer, it meant adapting the semaglutide synthesis (the same peptide active) to a continuous chemical synthesis process, and validating an oral dose-uniformity assay that was different from the injectable
References and more info This post is part of our series on Medicare coverage for cardiovascular health
doi: 10.1111/j.1464-5491.2010.03009.x
Their findings, however, proved inconclusive
